Postoperative irradiation in endometrial cancer: still a matter of controversy

Although endometrial cancer is the most common female malignancy, evidence- based uniform guidelines for postoperative therapy have not been establishe d. The most logical management is adjuvant irradiation tailored to the exte nt of surgery, the tumour grade, depth of myometrial invasion, degree of ly mph node involvement and age of the patient. Currently the only widely acce pted treatment recommendations are no further therapy in low-risk patients who underwent extensive surgical staging, and external beam radiotherapy (E BRT) in high-risk patients. Most authors recommend postoperative applicatio n of only one radiotherapy modality: either brachytherapy (BRT) or EBRT, as their routine combination does not clearly improve the outcome but does in crease the risk of late complications. A combination of BRT and EBRT should however be considered in patients with stage II disease, for infiltration of the lower uterine segment, vaginal involvement, positive or close surgic al margins, capillary space involvement or unfavourable histology. Two rece nt randomized studies including mostly intermediate-risk patients managed w ith either extensive surgical staging or total abdominal hysterectomy and b ilateral salpingo-oophorectomy (TAH&BSO) with or without postoperative EBRT , showed better local control but no survival benefit from adjuvant irradia tion. Two ongoing Gynecologic Oncology Group (GOG) studies compare adjuvant chemotherapy with pelvic or abdominal irradiation in patients with high ri sk of local relapse. The role of adjuvant radiotherapy (EBRT with or withou t BRT) in high-risk patients as well as the value of lymphadenectomy in pat ients fit for such surgery is being addressed in a trial co-ordinated by th e Medical Research Council. Future studies are warranted to define whether any irradiation should be employed in intermediate-risk patients and which radiotherapy modality should be used in high-risk node-negative patients wi th stage I tumours (stage Ib grade 3 and all stage Ic). Other issues which should be addressed in future studies include the extent of surgery, the ro le of systemic therapies, the relevance of novel biologic prognostic factor s, salvage therapies after recurrence, cost-benefit analysis and quality of life. (C)2001 Harcourt Publishers Ltd.